

# From lead to pre-clinical candidate and proof-of-concept in small-animal and non-human primate models

Work Package 6



## Leads



**Roger Le Grand**  
Academic Lead, CEA



**Helen Fletcher**  
Industry Lead, Janssen

## Key Objectives of WP 6

- ADME & PBPK evaluation of lead compounds before in vivo studies
- In vivo efficacy of lead compounds in small rodents (mouse, hamster incl. transgenic mice) expressing human ACE2. Evaluation of most promising leads for efficacy and safety in Non-Human Primate (NHP) model

## CONNECTIONS

with other work packages



### Work package 1-3

Perform proof of concept/in vivo efficacy and safety evaluation of lead small molecules discovered in WP1-3, as well as evaluating ADME/PK properties

### Work package 4

Perform proof of concept/in vivo efficacy and safety evaluation of antibodies discovered in WP4, as well as evaluating ADME/PK properties

## BREAKTHROUGH moments

2020

Establishment of hACE2-KI, K18 mouse models and the Syrian Hamster model against SARS-COV-2

2021

Non-human primate model for SARS-CoV-2 infection and disease is fully characterised and knowledge disseminated to the community

2021-4

Evaluation of efficacy of multiple small molecules and antibodies in-vivo against SARS-CoV-2 (multiple variants)

## KEY STATISTICS

4

In-vivo animal models set up


10

Lead small molecules tested in-vivo (Rodent)



Antibodies tested in-vivo for efficacy (NHP)

5



In-vivo experiments conducted

7

Publications

## PUBLIC DELIVERABLES



- D6.1 Report on rodent models (Nov 2020)
- D6.2 Report on suitability of mouse adapted SARS-CoV-2 virus for lethal humanised ACE-2 model (March 2021)
- D6.3 Report on reverse genetics system (Sept 2020)
- D6.7 Report on rodent model (Mar 2021)
- D6.11 Harmonisation SOP across WP1-7

## Partner Organisations

